Exemplary performance data for immunosuppressants

Analytical performance of clinically relevant compounds

TSQ Quantis MD Triple-Stage Quadrupole Mass Spectrometer | Vanquish MD HPLC

Preface

Liquid chromatography systems

Intended use: The Thermo Scientific[™] Vanquish[™] MD HPLC (high performance liquid chromatograph) is a general purpose laboratory instrument intended to separate drugs or compounds in human specimens. For *in vitro* diagnostic use only by trained, qualified laboratory personnel.

Indications for use: The Vanquish MD HPLC will be used by clinical diagnostic laboratories as a component of a laboratory developed test (LDT) method or workflow.

Contraindications of use: For *in vitro* diagnostic applications only. The Vanquish MD HPLC is to be operated only with hardware or software approved for *in vitro* diagnostic application.

Limitations of use: The Vanquish MD HPLC is compatible with the following Thermo Fisher Scientific instruments: Thermo Scientific[™] TSQ Altis[™] MD Series and Thermo Scientific[™] TSQ Quantis[™] MD Series mass spectrometers.



Mass spectrometers

Intended use: The TSQ Quantis MD Series mass spectrometer is intended to identify and quantify inorganic and organic compounds in human specimens. For *in vitro* diagnostic use only by trained, qualified laboratory personnel.

Indications for use: The TSQ Quantis MD Series mass spectrometer will be used by clinical diagnostic laboratories as a component of a laboratory developed test (LDT) method or workflow.

Contraindications of use: For *in vitro* diagnostic applications only. The TSQ Quantis MD Series mass spectrometer is to be operated only with hardware or software labeled for *in vitro* diagnostic use.

Limitations of use: The TSQ Quantis MD Series mass spectrometer is compatible with the Vanquish MD HPLC.



Exemplary performance data

Liquid chromatography tandem mass spectrometry systems enable robust and reliable *in vitro* quantification of a variety of compounds in biological matrices. The performance data presented in this paper is for illustrative purposes only and may not represent the performance that laboratories will obtain. Thermo Fisher Scientific does not recommend or suggest analysis of the analytes described herein using its systems. Performance in an individual laboratory may differ from what is presented in this document due to factors, including but not limited to laboratory methods, materials used, operator technique, and system conditions. It is the laboratory's responsibility to validate performance of any assay it intends to utilize in its facility and to comply with all applicable laws and policies.

Materials and methods

Samples

Sample preparation

Protein precipitation with ZnSO₄ followed by transfer to HPLC vial.

| Calibrators and controls | | | | |
|--------------------------|---------------|---|--|--|
| Calibrators | Art. No. 9933 | RECIPE [®] ClinCal [®] Whole Blood Calibrators for Immunosuppressants Levels 0–6 (RECIPE Chemicals + Instruments GmbH), LOT#1428 | | |
| Calibrator | Art. No. 9028 | RECIPE [®] ClinCal [®] Whole Blood Calibrators for Immunosuppressants Level 7 (Iris Technologies International GmbH) | | |
| Controls | Art. No. 8833 | RECIPE [®] ClinCheck [®] Whole Blood Controls for Immunosuppressants Levels I–III (Iris Technologies International GmbH) | | |
| Controls | Art. No 8903 | RECIPE [®] ClinCheck [®] Whole Blood Controls for Immunosuppressants Levels IV–V (Iris Technologies International GmbH) | | |

Liquid chromatography

- Mobile phase A: 0.1% formic acid and 10 mM of ammonium formate in water.
- Mobile phase B: 0.1% formic acid and 10 mM of ammonium formate in methanol.

Mass spectrometry

- Duration: 3 minutes
- Positive polarity: HESI
- Transitions: SRM
- Source conditions: Default

Instruments

For intra-system and inter-system precision, TSQ Quantis MD Series MS #1 was tested with Vanquish MD HPLC #1, #2 and #3. Vanquish MD HPLC #1 was also tested with TSQ Quantis MD Series MS #2 and #3. For between-day precision, testing was continued for TSQ Quantis MD Series MS #3 and Vanquish MD HPLC #1.

| Test configurations | | | | |
|--|------------------------|---|--|--|
| TSQ Quantis MD #1 | Vanquish MD HPLC #1 | Vanquish MD HPLC #2 | Vanquish MD HPLC #3 | |
| TSQ Quantis MD #2 | Vanquish MD HPLC #1 | TSQ Series II Thermo Scientific [™] TSQ Altis [™] MD and Quantis MD software for system calibration, diagnostics, compound | | |
| TSQ Quantis Vanquish MD MD #3 HPLC #1 | Vanguish MD | optimization and development. | method | |
| | HPLC #1 | Thermo Scientific LDT Software for | [™] TraceFinder [™] quantitation. | |

Acceptance criteria

Acceptance criteria, based on five injections of each commercial control sample, are shown in the table below:

| Acceptance criteria | | | |
|---------------------|---|--|--|
| Accuracy | Difference between the assigned and measured value of control samples at low, medium and high levels $<\pm15\%$ | | |
| Imprecision | CV at low, medium and high levels of control samples ${<}15\%$ | | |
| CLSI | Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline. CLSI document C62-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014. | | |

Results

Vanquish MD HPLC

| TSQ Quantis MD #1 Vanquish MD HPLC #1 n=5 | Calibrator %Diff | B^2 | QC% Diff | QC1 %RSD | QCIII %RSD | OCV %RSD |
|---|---------------------|----------------|----------|---------------|---------------|-------------|
| Cyclosporin A | Pass | 0.998 (pass) | pass | 6.08 (pass) | 6.17 (pass) | 5.03 (pass) |
| Everolimus | Pass | 0.9974 (pass) | pass | 7.70 (pass) | 4.78 (pass) | 3.93 (pass) |
| Sirolimus | Pass | 0.9972 (pass) | pass | 6.67 (pass) | 5.51 (pass) | 3.64 (pass) |
| Tacrolimus | Pass | 0.9977 (pass) | pass | 4.77 (pass) | 2.95 (pass) | 1.92 (pass) |
| TSQ Quantis MD #1 | 1 400 | cicci i (pacc) | paoo | (1117 (19400) | 2.000 (p0.00) | 1102 (pado) |
| Vanquish MD HPLC #2 | Calibrator | | | | | |
| n=5 | %Diff | R^2 | QC% Diff | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | Pass | 0.9998 (pass) | pass | 0.64 (pass) | 0.70 (pass) | 1.26 (pass) |
| Everolimus | Pass | 0.9991 (pass) | pass | 3.03 (pass) | 1.72 (pass) | 0.41 (pass) |
| Sirolimus | Pass | 0.9981 (pass) | pass | 3.77 (pass) | 1.58 (pass) | 1.37 (pass) |
| Tacrolimus | Pass | 0.9978 (pass) | pass | 1.73 (pass) | 1.66 (pass) | 0.73 (pass) |
| TSQ Quantis MD #1 | Calibrator | | | | | |
| n=5 | %Diff | R^2 | QC% Diff | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | Pass | 0.9996 (pass) | pass | 0.27 (pass) | 0.51 (pass) | 1.01 (pass) |
| Everolimus | Pass | 0.9989 (pass) | pass | 3.70 (pass) | 0.57 (pass) | 1.30 (pass) |
| Sirolimus | Pass | 0.9983 (pass) | pass | 2.37 (pass) | 1.10 (pass) | 0.83 (pass) |
| Tacrolimus | Pass | 0.9976 (pass) | pass | 1.79 (pass) | 1.43 (pass) | 0.49 (pass) |
| TSQ Quantis MD #2 | | | | | | |
| Vanquish MD HPLC #1 | Calibrator | DA2 | | | | |
| | Rass | 0.0072 (page) | | | | |
| Everelimus | Pass | 0.9975 (pass) | pass | 5.33 (pass) | 2.64 (pass) | 2.20 (pass) |
| Sirolimus | Pass | 0.9995 (pass) | pass | 3.50 (pass) | 1.08 (pass) | 5.07 (pass) |
| Tagrolimus | Pass | 0.9900 (pass) | pass | 1.05 (pass) | 2.65 (pass) | 2.40 (pass) |
| TSO Quantis MD #3 | F 455 | 0.9900 (pass) | pass | 1.90 (pass) | 2.00 (pass) | 2.49 (pass) |
| Vanquish MD HPLC #1 | Calibrator | | | | | |
| n=5 (Day One) | %Diff | R^2 | QC% Diff | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | Pass | 0.9998 (pass) | pass | 0.34 (pass) | 0.30 (pass) | 0.32 (pass) |
| Everolimus | Pass | 0.9989 (pass) | pass | 2.29 (pass) | 0.94 (pass) | 2.22 (pass) |
| Sirolimus | Pass | 0.9984 (pass) | pass | 2.95 (pass) | 0.55 (pass) | 1.75 (pass) |
| Tacrolimus | Pass | 0.9981 (pass) | pass | 1.87 (pass) | 0.60 (pass) | 1.09 (pass) |
| TSQ Quantis MD #3 | Calibrator | | | | | |
| n=5 (Day Two) | %Diff | R^2 | QC% Diff | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | Pass | 0.9996 (pass) | pass | 0.50 (pass) | 0.46 (pass) | 0.21 (pass) |
| Everolimus | Pass | 0.9994 (pass) | pass | 3.03 (pass) | 1.49 (pass) | 0.91 (pass) |
| Sirolimus | Pass | 0.9986 (pass) | pass | 2.85 (pass) | 0.85 (pass) | 0.84 (pass) |
| Tacrolimus | Pass | 0.9988 (pass) | pass | 1.47 (pass) | 1.04 (pass) | 0.46 (pass) |
| TSQ Quantis MD #3 | | | | | | |
| Vanquish MD HPLC #1 | Calibrator | 5.0 | | | | |
| h=5 (Day Three) | %Diii | R*2 | QC% Diff | QC1 %RSD | | QCV %RSD |
| Cyclosporin A | Pass | 0.9997 (pass) | pass | 0.58 (pass) | 0.42 (pass) | 0.40 (pass) |
| Everolimus | Pass | 0.999 (pass) | pass | 4.13 (pass) | 1.33 (pass) | 0.83 (pass) |
| Sirolimus | Pass | 0.998 (pass) | pass | 3.45 (pass) | 0.56 (pass) | 0.76 (pass) |
| lacrolimus | Pass | 0.9983 (pass) | pass | 2.22 (pass) | 1.06 (pass) | 0.77 (pass) |

Vanquish MD HPLC (Continued)

| TSQ Quantis MD #1 Vanquish MD HPLC #1 Vanquish MD HPLC #2 Vanquish MD HPLC #3 n=15 | QC1 %RSD | QCIII %RSD | QCV %RSD |
|--|-------------|-------------|-------------|
| Cyclosporin A | 3.32 (pass) | 3.35 (pass) | 2.84 (pass) |
| Everolimus | 4.91 (pass) | 3.31 (pass) | 3.00 (pass) |
| Sirolimus | 4.71 (pass) | 3.81 (pass) | 2.62 (pass) |
| Tacrolimus | 3.36 (pass) | 3.01 (pass) | 1.25 (pass) |
| TSQ Quantis MD #1 TSQ Quantis MD #2 TSQ Quantis MD #3 (Day One) Vanquish MD HPLC #1 | | | |
| n=15 | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | 3.34 (pass) | 3.47 (pass) | 3.65 (pass) |
| Everolimus | 5.38 (pass) | 4.01 (pass) | 3.70 (pass) |
| Sirolimus | 4.55 (pass) | 3.91 (pass) | 4.01 (pass) |
| lacrolimus | 3.10 (pass) | 3.11 (pass) | 1.88 (pass) |
| TSQ Quantis MD #3 (Day One) TSQ Quantis MD #3 (Day Two) TSQ Quantis MD #3 (Day Three) Vanquish MD HPLC #1 n=15 | QC1 %RSD | QCIII %RSD | QCV %RSD |
| Cyclosporin A | 0.83 (pass) | 0.55 (pass) | 0.75 (pass) |
| Everolimus | 4.00 (pass) | 2.18 (pass) | 1.85 (pass) |
| Sirolimus | 4.15 (pass) | 1.53 (pass) | 2.31 (pass) |
| Tacrolimus | 1.74 (pass) | 0.96 (pass) | 1.04 (pass) |
| TSQ Quantis MD #1 Vanquish MD HPLC #1 Vanquish MD HPLC #2 Vanquish MD HPLC #3 TSQ Quantis MD #2 Vanquish MD HPLC #1 TSQ Quantis MD #3 (Day One) TSQ Quantis MD #3 (Day Two) TSQ Quantis MD #3 (Day Three) Vanquish MD HPLC #1 n=35 | OC1 %BSD | | OCV %BSD |
| Cvclosporin A | 2.23 (pass) | 2.31 (pass) | 2.55 (pass) |
| Everolimus | 4.56 (pass) | 2.79 (pass) | 2.60 (pass) |
| Sirolimus | 4.23 (pass) | 2.81 (pass) | 2.97 (pass) |
| Tacrolimus | 2.62 (pass) | 2.35 (pass) | 1.39 (pass) |

Chromatogram for QC III run on TSQ Quantis MD #2 and Vanquish MD HPLC



From top to bottom: Cyclosporin A, Everolimus, Sirolimus and Tacrolimus

thermo scientific

MS² Spectra for QC III run on TSQ Quantis MD #2 and Vanquish MD HPLC



From top to bottom: Cyclosporin A, Everolimus, Sirolimus and Tacrolimus. Greater relative abundance quantifier ion. Lesser relative abundance confirming ion.

Find out more at thermofisher.com/BeSure

IVD In Vitro Diagnostic Medical Device

© 2020 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. RECIPE is a registered trademark of RECIPE Chemicals + Instruments GmbH. This information is presented as an example of the capabilities of Thermo Fisher Scientific Inc. products. It is not intended to encourage use of these products in any manners that might infringe the intellectual property rights of others. Specifications, terms and pricing are subject to change. Not all products are available in all locations. Please consult your local sales representative for details. **DS73381-EN 0920M**

